NantHealth, Inc. (NASDAQ: NHIQ) is a health technology company that develops and delivers integrated software and molecular diagnostics solutions to enhance patient care and accelerate clinical decision-making. Leveraging advanced data analytics and high-throughput genomic profiling, the company’s Precision Medicine platforms aim to provide clinicians with actionable insights throughout the entire patient journey. NantHealth’s offerings encompass diagnostic assays, point-of-care connectivity, and cloud-based informatics tools designed to streamline workflows and support precision oncology, immunotherapy and chronic disease management.
The company’s flagship product, the GPS Cancer assay, delivers comprehensive genomic profiling by analyzing tumor tissue and circulating biomarkers to identify actionable mutations, potential therapeutic targets and resistance mechanisms. Alongside this, NantHealth’s OncoSpan next-generation sequencing panel offers multigene testing for solid tumors, while its Proactive Molecular™ screening supports early detection strategies. These diagnostics are complemented by the NantOS™ Precision Medicine Cloud, a secure platform that aggregates genomic, clinical, imaging and laboratory data to facilitate real-time decision support and multidisciplinary collaboration.
Headquartered in Culver City, California, NantHealth serves a network of hospitals, academic medical centers and commercial laboratories across the United States, with strategic partnerships extending into Europe and Asia. The company collaborates with pharmaceutical and biotechnology firms on clinical trials, co-develops companion diagnostics and integrates its informatics solutions with electronic health record systems to promote interoperability and value-based care models.
Founded in 2012 by physician-scientist Dr. Patrick Soon-Shiong, NantHealth went public in 2016 to advance its mission of transforming medicine through data-driven insights. Dr. Soon-Shiong continues to lead the company as Chairman and Chief Executive Officer, supported by a management team of seasoned executives with expertise in oncology, diagnostics, software engineering and health economics. Together, they strive to expand access to precision medicine and improve outcomes for patients worldwide.
AI Generated. May Contain Errors.
Free NHIQ Stock Alerts